ReviewResearch (Washington, D.C.)2025
Microneedle Technology for Overcoming Biological Barriers: Advancing Biomacromolecular Delivery and Therapeutic Applications in Major Diseases.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Mechanical-Enhanced Porous Silk-Based Cryogenic Microneedles for Cell Thawing/Revival in the Gastric Wall.Polymers · 2026Article
- Highly cited original research in microneedle science from 2015 to 2025 a bibliometric and altmetric analysis.Discover nano · 2026Review
- Review
- Microneedle Technologies for Drug Delivery: Innovations, Applications, and Commercial Challenges.Micromachines · 2026Review
- Evolution of 3D-Printed Microneedles toward Closed-Loop Theranostic Platforms.Research (Washington, D.C.) · 2026Review
- A State-of-the-Art Overview on (Epi)Genomics and Personalized Skin Rejuvenating Strategies.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomacromolecules are now widely employed in the therapy of major diseases such as tumors, infections, cardiovascular diseases, metabolic diseases, and autoimmune diseases. Although significant advances have been made in their application, their administration is largely dependent on professional injection, which causes pain, massive medical waste, and high medical burden. As a novel delivery system, microneedles pierce the stratum corneum to assist in intradermal drug delivery, exhibiting minimal invasiveness, high delivery efficiency, and improved patient compliance. The evolution of biomaterials and tissue engineering has broadened microneedle utilization to encompass oral and cardiovascular therapies. Herein, we discuss research advancements regarding the development of biomacromolecule-laden microneedles for treating major diseases. We present detailed examples on how to devise functional microneedles to cross drug delivery barriers in the skin, heart, and blood vessels for improved therapeutic outcomes. Furthermore, we discuss the critical barriers in industrial-scale fabrication and transitioning into clinical practice of microneedles, aiming to provide insightful solutions. Moreover, we explore the future applications of microneedles, including the development of microneedle tacks, robots, and biomimetics to combat intractable diseases. We believe that this review will aid in the designing of microneedles for biomacromolecule delivery, opening up a new avenue for the treatment of major diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.